LGALS9 and melanoma: For example, studies in non-CNS cancers have shown that high expression of Galectin-9 was correlated with an improved outcome for patients diagnosed with breast cancer, melanoma, HCC, colon cancer, as well as bladder urothelial carcinoma (99, 100, 102–106).